A Sacramento company whose eye-scanning test to pinpoint Alzheimer’s was developed at Cedars-Sinai has raised $11.2 million in financing.
NeuroVision Imaging Inc. on May 2 announced a series C financing round of $15 million with an initial close of $11.2 million. It holds commercial rights to the eye-imaging technology licensed from the Beverly Grove medical center.
The financing will provide support for NeuroVision as it seeks federal approval for its noninvasive eye imaging system that Cedars-Sinai researchers say can allow for early low-cost screening, detection and treatment of the debilitating cognitive disease.
Locating protein plaques associated with the disease now often require costly PET scans or invasive spinal taps.
The advance in imaging technology, detailed in a peer-reviewed study published last August, could both save money for hospitals and make Cedars-Sinai and NeuroVision a profit if the companies can secure U.S. Food and Drug Administration approval.
NeuroVision Imaging was co-founded by Dr. Keith L. Black, chair of the Cedar-Sinai Department of Neurosurgery, and Maya Koronyo-Hamaoui, an associate professor of neurosurgery and biomedical sciences at the Cedars-Sinai Maxine Dunitz Neurosurgical Institute.
The financing round was led by Wildcat Capital Management, of Fort Worth, Texas and included investments by Johnson & Johnson Innovation, Nicon-SBI Innovation Fund, Whittier Ventures and VSP Global.
Health business reporter Dana Bartholomew can be reached at firstname.lastname@example.org. Follow him on Twitter @_DanaBart.
For reprint and licensing requests for this article, CLICK HERE.